Impact of Convalescent Plasma Therapy in Hospitalized Patients With Severe COVID-19
- 1 November 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 30 (6) , 1-6
Abstract
Background Convalescent plasma (CP) is often administered to hospitalized patients with COVID-19, but the impact on clinical outcomes has varied across different patient populations. Methods A retrospective, propensity score–matched controlled study was conducted to compare outcomes of hospitalized patients with nonmechanically ventilated severe COVID-19 who received CP within 36 hours of hospital admission with those who did not receive CP during their hospitalization. A combination of propensity score matching and Mahalanobis distance matching was used. Results One hundred forty-three patients were originally in the treatment group, and 94 were able to be matched to control patients who did not receive CP during their hospital stay. Receipt of early CP was not associated with significant differences in clinical outcomes. Overall 30-day mortality was 12.8% in the CP group and 14.9% in the non-CP group (P = 0.67). No significant differences were observed between the early CP group and the non-CP group for 30-day readmissions (12.8% vs 9.6%; P = 0.47), subsequent transfer to an intensive care unit (2.1% vs 2.1%; P = 1.0), and subsequent progression to noninvasive ventilation after 36 hours from admission (12.8% vs 5.3%; P = 0.07). Receipt of early CP was associated with increased need for mechanical ventilation after 36 hours from admission (12.8% vs 3.2%; P = 0.013). Conclusions Receipt of early CP for hospitalized patients with severe COVID-19 but not requiring mechanical ventilation was not associated with improvements in clinical status or mortality compared with matched patients who did not receive CP.Keywords
This publication has 21 references indexed in Scilit:
- Safety UpdateMayo Clinic Proceedings, 2020
- Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent PlasmaThe American Journal of Pathology, 2020
- Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19JAMA, 2020
- Effectiveness of convalescent plasma therapy in severe COVID-19 patientsProceedings of the National Academy of Sciences, 2020
- Evaluation of Convalescent Plasma for Ebola Virus Disease in GuineaNew England Journal of Medicine, 2016
- Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus InfectionClinical Infectious Diseases, 2011
- Treatment with Convalescent Plasma for Influenza A (H5N1) InfectionNew England Journal of Medicine, 2007
- Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?Annals of Internal Medicine, 2006
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Use of Intravenous Immunoglobulins for Prophylaxis or Treatment of Infectious DiseasesClinical and Diagnostic Laboratory Immunology, 2001